0
0
Health authorities in the United States, led by Health and Human Services Secretary Robert F. Kennedy Jr., are intensifying efforts to regulate and restrict 7-hydroxymitragynine (7-OH), a potent opioid-like compound derived from the kratom plant. This move comes amid concerns about the rising popularity and significant addictive potential of 7-OH products, which are increasingly available in various forms such as energy drinks, gummies, capsules, and powders, often sold at convenience stores, gas stations, and smoke shops.
Kratom, a plant native to Southeast Asia, has long been used as an herbal remedy for pain relief and energy enhancement. However, the concentrated compound 7-OH, extracted or synthetically produced from kratom, binds strongly to opioid receptors in the brain, making it considerably more potent and addictive than the natural kratom leaf itself. FDA Commissioner Dr. Marty Makary has highlighted that 7-OH is an opioid and is estimated to be many times stronger than morphine.
The FDA has issued warning letters to several companies marketing products containing 7-OH, asserting that these products have not been evaluated for safety and are not approved as dietary supplements or food additives. The agency is recommending that 7-OH be classified as a controlled substance under federal law, a proposal that will undergo review by the Drug Enforcement Administration before any nationwide ban takes effect.
Secretary Kennedy emphasized that this action is a critical step in combating the opioid crisis and protecting public health, warning of the potential for a new wave of addiction fueled by unregulated and misleadingly marketed kratom-derived products. There are particular concerns about products targeted at younger consumers, including gummy bear-shaped and brightly colored items that disguise the presence of addictive substances.
Medical experts and advocacy groups have also raised alarms about the health risks associated with 7-OH, including addiction, liver damage, withdrawal symptoms, and even death. Social media platforms have seen growing warnings from individuals who have experienced severe adverse effects related to kratom and 7-OH use.
While natural kratom leaf products remain legal in many places, some states have enacted bans, and federal authorities continue to monitor the situation closely. The government’s approach aims to differentiate between natural kratom and the concentrated or synthetic 7-OH compounds, focusing regulatory efforts on the latter due to its high risk of abuse.
This regulatory initiative reflects ongoing efforts to curb the proliferation of dangerous psychoactive substances in consumer products and prevent further public health crises related to opioid addiction.
Disclaimer: This article is based on current information and regulatory announcements as of August 2025. The legal status and health implications of kratom and 7-hydroxymitragynine may vary by jurisdiction and are subject to change as new research and regulatory decisions emerge. Always consult healthcare professionals for advice on substance use and treatment options.
